AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as well as data on its
Click here to view original post